Michael Feyder1, Erik Södersten2, Emanuela Santini1, Vincent Vialou3, Quincey LaPlant4, Emily L Watts4, Giada Spigolon1, Klaus Hansen5, Jocelyne Caboche6, Eric J Nestler4, Gilberto Fisone7. 1. Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. 2. Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Biotech Research and Innovation Centre and Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark. 3. Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Institut National de la Santé et de la Recherche Médicale, Le Centre national de la recherche scientifique Unités Mixtes de Recherche 7224, Université Pierre et Marie Curie, Paris, France. 4. Fishberg Department of Neuroscience and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 5. Biotech Research and Innovation Centre and Centre for Epigenetics, University of Copenhagen, Copenhagen, Denmark. 6. Institut National de la Santé et de la Recherche Médicale, Le Centre national de la recherche scientifique Unités Mixtes de Recherche 7224, Université Pierre et Marie Curie, Paris, France. 7. Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. Electronic address: gilberto.fisone@ki.se.
Abstract
BACKGROUND: Abnormal regulation of extracellular signal-regulated kinases 1 and 2 has been implicated in 3,4-dihydroxy-l-phenylalanine (L-DOPA)-induced dyskinesia (LID), a motor complication affecting Parkinson's disease patients subjected to standard pharmacotherapy. We examined the involvement of mitogen- and stress-activated kinase 1 (MSK1), a downstream target of extracellular signal-regulated kinases 1 and 2, and an important regulator of transcription in LID. METHODS: 6-Hydroxydopamine was used to produce a model of Parkinson's disease in MSK1 knockout mice and in ∆FosB- or ∆cJun-overexpressing transgenic mice, which were assessed for LID following long-term L-DOPA administration. Biochemical processes were evaluated by Western blotting or immunofluorescence. Histone H3 phosphorylation was analyzed by chromatin immunoprecipitation followed by promotor-specific quantitative polymerase chain reaction. RESULTS: Genetic inactivation of MSK1 attenuated LID and reduced the phosphorylation of histone H3 at Ser10 in the striatum. Chromatin immunoprecipitation analysis showed that this reduction occurred at the level of the fosB gene promoter. In line with this observation, the accumulation of ∆FosB produced by chronic L-DOPA was reduced in MSK1 knockout. Moreover, inducible overexpression of ∆FosB in striatonigral medium spiny neurons exacerbated dyskinetic behavior, whereas overexpression of ∆cJun, which reduces ∆FosB-dependent transcriptional activation, counteracted LID. CONCLUSIONS: Results indicate that abnormal regulation of MSK1 contributes to the development of LID and to the concomitant increase in striatal ∆FosB, which may occur via increased histone H3 phosphorylation at the fosB promoter. Results also show that accumulation of ∆FosB in striatonigral neurons is causally related to the development of dyskinesia.
BACKGROUND: Abnormal regulation of extracellular signal-regulated kinases 1 and 2 has been implicated in 3,4-dihydroxy-l-phenylalanine (L-DOPA)-induced dyskinesia (LID), a motor complication affecting Parkinson's diseasepatients subjected to standard pharmacotherapy. We examined the involvement of mitogen- and stress-activated kinase 1 (MSK1), a downstream target of extracellular signal-regulated kinases 1 and 2, and an important regulator of transcription in LID. METHODS:6-Hydroxydopamine was used to produce a model of Parkinson's disease in MSK1 knockout mice and in ∆FosB- or ∆cJun-overexpressing transgenic mice, which were assessed for LID following long-term L-DOPA administration. Biochemical processes were evaluated by Western blotting or immunofluorescence. Histone H3 phosphorylation was analyzed by chromatin immunoprecipitation followed by promotor-specific quantitative polymerase chain reaction. RESULTS: Genetic inactivation of MSK1attenuated LID and reduced the phosphorylation of histone H3 at Ser10 in the striatum. Chromatin immunoprecipitation analysis showed that this reduction occurred at the level of the fosB gene promoter. In line with this observation, the accumulation of ∆FosB produced by chronic L-DOPA was reduced in MSK1 knockout. Moreover, inducible overexpression of ∆FosB in striatonigral medium spiny neurons exacerbated dyskinetic behavior, whereas overexpression of ∆cJun, which reduces ∆FosB-dependent transcriptional activation, counteracted LID. CONCLUSIONS: Results indicate that abnormal regulation of MSK1 contributes to the development of LID and to the concomitant increase in striatal ∆FosB, which may occur via increased histone H3 phosphorylation at the fosB promoter. Results also show that accumulation of ∆FosB in striatonigral neurons is causally related to the development of dyskinesia.
Authors: J P Doucet; Y Nakabeppu; P J Bedard; B T Hope; E J Nestler; B J Jasmin; J S Chen; M J Iadarola; M St-Jean; N Wigle; P Blanchet; R Grondin; G S Robertson Journal: Eur J Neurosci Date: 1996-02 Impact factor: 3.386
Authors: M-C Peakman; C Colby; L I Perrotti; P Tekumalla; T Carle; P Ulery; J Chao; C Duman; C Steffen; L Monteggia; M R Allen; J L Stock; R S Duman; J D McNeish; M Barrot; D W Self; E J Nestler; E Schaeffer Journal: Brain Res Date: 2003-04-25 Impact factor: 3.252
Authors: Shiaoching Gong; Chen Zheng; Martin L Doughty; Kasia Losos; Nicholas Didkovsky; Uta B Schambra; Norma J Nowak; Alexandra Joyner; Gabrielle Leblanc; Mary E Hatten; Nathaniel Heintz Journal: Nature Date: 2003-10-30 Impact factor: 49.962
Authors: Sara Sanz-Blasco; Melina P Bordone; Ana Damianich; Gimena Gomez; M Alejandra Bernardi; Luciana Isaja; Irene R Taravini; Diane P Hanger; M Elena Avale; Oscar S Gershanik; Juan E Ferrario Journal: Mol Neurobiol Date: 2017-08-24 Impact factor: 5.590
Authors: Kathy Steece-Collier; Timothy J Collier; Jack W Lipton; Jennifer A Stancati; Mary E Winn; Allyson Cole-Strauss; Rhyomi Sellnow; Melissa M Conti; Natosha M Mercado; Eduardo A Nillni; Caryl E Sortwell; Fredric P Manfredsson; Christopher Bishop Journal: Exp Neurol Date: 2020-05-05 Impact factor: 5.330
Authors: Nikhil M Urs; Simone Bido; Sean M Peterson; Tanya L Daigle; Caroline E Bass; Raul R Gainetdinov; Erwan Bezard; Marc G Caron Journal: Proc Natl Acad Sci U S A Date: 2015-04-27 Impact factor: 11.205
Authors: Melina P Bordone; Ana Damianich; M Alejandra Bernardi; Tomas Eidelman; Sara Sanz-Blasco; Oscar S Gershanik; M Elena Avale; Juan E Ferrario Journal: eNeuro Date: 2021-06-07